1-179551371-G-A
Position:
Variant summary
Our verdict is Benign. Variant got -21 ACMG points: 0P and 21B. BP4_StrongBP6_Very_StrongBP7BA1
The NM_014625.4(NPHS2):c.954C>T(p.Ala318=) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.618 in 1,613,796 control chromosomes in the GnomAD database, including 308,950 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).
Frequency
Genomes: 𝑓 0.61 ( 28814 hom., cov: 31)
Exomes 𝑓: 0.62 ( 280136 hom. )
Consequence
NPHS2
NM_014625.4 synonymous
NM_014625.4 synonymous
Scores
2
Clinical Significance
Conservation
PhyloP100: -0.562
Genes affected
NPHS2 (HGNC:13394): (NPHS2 stomatin family member, podocin) This gene encodes a protein that plays a role in the regulation of glomerular permeability. Mutations in this gene cause steroid-resistant nephrotic syndrome. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2014]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -21 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.72).
BP6
Variant 1-179551371-G-A is Benign according to our data. Variant chr1-179551371-G-A is described in ClinVar as [Benign]. Clinvar id is 260432.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr1-179551371-G-A is described in Lovd as [Benign].
BP7
Synonymous conserved (PhyloP=-0.562 with no splicing effect.
BA1
GnomAd4 highest subpopulation (AMR) allele frequency at 95% confidence interval = 0.628 is higher than 0.05.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
NPHS2 | NM_014625.4 | c.954C>T | p.Ala318= | synonymous_variant | 8/8 | ENST00000367615.9 | NP_055440.1 | |
AXDND1 | NM_144696.6 | c.3032-3141G>A | intron_variant | ENST00000367618.8 | NP_653297.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
NPHS2 | ENST00000367615.9 | c.954C>T | p.Ala318= | synonymous_variant | 8/8 | 1 | NM_014625.4 | ENSP00000356587 | P1 | |
AXDND1 | ENST00000367618.8 | c.3032-3141G>A | intron_variant | 1 | NM_144696.6 | ENSP00000356590 | P2 |
Frequencies
GnomAD3 genomes AF: 0.614 AC: 93257AN: 151874Hom.: 28786 Cov.: 31
GnomAD3 genomes
AF:
AC:
93257
AN:
151874
Hom.:
Cov.:
31
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.619 AC: 155359AN: 250964Hom.: 48514 AF XY: 0.618 AC XY: 83835AN XY: 135584
GnomAD3 exomes
AF:
AC:
155359
AN:
250964
Hom.:
AF XY:
AC XY:
83835
AN XY:
135584
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.618 AC: 903486AN: 1461802Hom.: 280136 Cov.: 60 AF XY: 0.618 AC XY: 449545AN XY: 727192
GnomAD4 exome
AF:
AC:
903486
AN:
1461802
Hom.:
Cov.:
60
AF XY:
AC XY:
449545
AN XY:
727192
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.614 AC: 93340AN: 151994Hom.: 28814 Cov.: 31 AF XY: 0.613 AC XY: 45530AN XY: 74282
GnomAD4 genome
AF:
AC:
93340
AN:
151994
Hom.:
Cov.:
31
AF XY:
AC XY:
45530
AN XY:
74282
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
1966
AN:
3478
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Benign
Submissions summary: Benign:11
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not specified Benign:4
Benign, no assertion criteria provided | clinical testing | Genome Diagnostics Laboratory, University Medical Center Utrecht | - | - - |
Benign, no assertion criteria provided | clinical testing | Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ | - | - - |
Benign, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | - | - - |
Benign, criteria provided, single submitter | clinical testing | Unidad de Genómica Garrahan, Hospital de Pediatría Garrahan | Jul 15, 2024 | This variant is classified as Benign based on local population frequency. This variant was detected in 86% of patients studied in a panel designed for Epileptic and Developmental Encephalopathy and Progressive Myoclonus Epilepsy. Number of patients: 80. Only high quality variants are reported. - |
not provided Benign:4
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Feb 01, 2024 | - - |
Benign, criteria provided, single submitter | clinical testing | GeneDx | Oct 18, 2019 | - - |
Benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jul 05, 2016 | Variant summary: The NPHS2 c.954C>T (p.Ala318Ala) variant involves the alteration of a non-conserved nucleotide resulting in a synonymous change. One in silico tool (MutationTaster) predicts a polymorphism outcome for this variant. 5/5 splice prediction tools predict no significant impact on normal splicing, howevere these predictions are yet to be confirmed by the functional studies. This variant was found in 75096/121278 control chromosomes (including 23360 homozygotes) at a frequency of 0.6192055, which is approximately 350 times the estimated maximal expected allele frequency of a pathogenic NPHS2 variant (0.0017678), suggesting this variant is a common benign polymorphism. The variant of interest has also been cited as a polymorphism in published reports (Rachmadi_2015). Taken together, this variant is classified as Benign. - |
Benign, criteria provided, single submitter | not provided | Breakthrough Genomics, Breakthrough Genomics | - | - - |
Nephrotic syndrome, type 2 Benign:2
Benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jan 12, 2018 | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. - |
Benign, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Jul 08, 2021 | - - |
Steroid-resistant nephrotic syndrome Benign:1
Benign, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 16, 2020 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at